Optimus Receives Tentative Approval from U.S. FDA for Brexpiprazole Tablets

Hyderabad (Telangana) [India], October 09: Optimus Pharma Private Limited today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for the generic equivalent of Rexulti® Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, of Otsuka Pharmaceutical Co., Ltd. Optimus Pharma’s approval for its Abbreviated New Drug Application (ANDA) BREXPIPRAZOLE Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, was received on October 8th, 2021. BREXPIPRAZOLE will be manufactured at Optimus Pharma’s Pashmylaram USFDA accredited facility in India.

BREXPIPRAZOLE Tablets (RLD: Rexulti® Tablets) had estimated annual sales of USD 1258 million in the U.S. (IQVIA MAT July 2021).

BREXPIPRAZOLE has a favourable antipsychotic profile in terms of improvement of cognitive performance and sleep patterns, as well as effects on affective states and potential to treat core symptoms in schizophrenia and major depressive disorder, including cognitive deficits with a low risk of adverse effects (extrapyramidal symptoms, metabolic complications, weight gain, akathisia potential) that are commonly encountered with other typical and second-generation antipsychotic drugs. From the studies done so far, it can be concluded that BREXPIPRAZOLE can be effective monotherapy for schizophrenia and as an adjunct to other antidepressant medications in major depressive disorder.

About Optimus Pharma

Optimus was established in the year 2004 as a custom synthesis laboratory by a team of techno-commercial experts. It is one of the fastest-growing Manufacturer in Active Pharmaceutical Ingredients (APIs) and Finished dosages. Over the last decade, we have been certified and audited by reputed Global Regulatory Agencies like USFDA, WHO, COFEPRIS, EMA, KFDA and AFM from PMDA Japan. Optimus Pharma is a vertically integrated pharmaceutical company engaged in the manufacturing of Solid Oral and semisolid formulations. We have successfully integrated our API and Formulation R&D teams, with the IP and Regulatory Affairs team in order to ensure a dynamic product portfolio. We help our customers serve global markets with technology based, innovative, cost effective & consumer friendly products of the highest quality.

Related Posts

Freshara Agro Exports Achieves Rs. 260+ Cr Total Revenue in FY25, Setting a New Milestone

Chennai (Tamil Nadu) [India], June 16:  Freshara Agro Exports Limited specializes in procurement, processing, and exporting preserved gherkins and pickled vegetables, has released its audited financial results for H2 FY25.…

LANXESS starts fiscal year 2025 with significant earnings increase

Mumbai (Maharashtra) [India], June 16: Specialty chemicals company LANXESS has started the 2025 fiscal year with a significant increase in earnings: EBITDA pre exceptionals rose by 31.7 percent from EUR…

You Missed

JPrime Buildcon’s Grand Business Meet ‘Sankalp 2025’ Marks a New Chapter in Mumbai 3.0 Growth Story

  • By
  • June 13, 2025
JPrime Buildcon’s Grand Business Meet ‘Sankalp 2025’ Marks a New Chapter in Mumbai 3.0 Growth Story

Surat’s Diamond Shines at Las Vegas: Govindkaka Felicitated at JCK Las Vegas

  • By
  • June 13, 2025
Surat’s Diamond Shines at Las Vegas: Govindkaka Felicitated at JCK Las Vegas

Celebs, Business and Beyond: How The Centrum Hotel Lucknow Became a New Luxury Landmark in India 2025

  • By
  • June 12, 2025
Celebs, Business and Beyond: How The Centrum Hotel Lucknow Became a New Luxury Landmark in India 2025

Ankit Khandelwal: The Relentless Visionary Behind Scalable Impact

  • By
  • June 11, 2025
Ankit Khandelwal: The Relentless Visionary Behind Scalable Impact

Bonhooghly Yubak Sangha’s Roktodan Utsav Sees 2,545 Donors in Major Kolkata Blood Drive

  • By
  • June 10, 2025
Bonhooghly Yubak Sangha’s Roktodan Utsav Sees 2,545 Donors in Major Kolkata Blood Drive

Morari Bapu Becomes An Inspiration For Environmental Action

  • By
  • June 7, 2025
Morari Bapu Becomes An Inspiration For Environmental Action